Equities

Dawnrays Pharmaceutical (Holdings) Ltd

Dawnrays Pharmaceutical (Holdings) Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.20
  • Today's Change-0.01 / -0.83%
  • Shares traded113.00k
  • 1 Year change-12.41%
  • Beta0.4617
Data delayed at least 15 minutes, as of May 22 2024 08:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.

  • Revenue in HKD (TTM)1.24bn
  • Net income in HKD351.53m
  • Incorporated2002
  • Employees1.14k
  • Location
    Dawnrays Pharmaceutical (Holdings) LtdUnits 3001-02, 30/F, CNT Tower, Wanchai Hong KongHKG
  • Phone+852 21119708
  • Fax+852 21119870
  • Websitehttps://www.dawnrays.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ascletis Pharma Inc61.03m-156.05m1.35bn219.00--0.5491--22.07-0.1466-0.14660.05682.420.0222.303.86278,667.70-5.62-6.43-5.91-6.6445.9235.67-255.70-243.3816.54-6.090.0036--4.63-19.3954.04---20.44--
Essex Bio-Technology Ltd1.71bn275.26m1.44bn1.48k5.420.74944.310.84470.46890.46892.873.390.61612.283.351,152,300.009.9411.2013.2114.7390.2086.0116.1319.771.46--0.132616.1629.517.7222.113.567.297.39
Wuhan YZY Biopharma Co Ltd-100.00bn-100.00bn1.44bn123.00-----------------------------------------------------1.50------
Mabpharm Ltd93.99m-225.75m1.48bn347.00--6.71--15.80-0.0548-0.05480.02280.05360.08930.11766.02270,855.50-21.44-21.42-28.92-27.4986.32---240.19-486.400.7596-19.030.5591--55.87--0.694---26.85--
Cryofocus Medtech Shanghai Co Ltd44.16m-105.12m1.48bn392.00--8.53--33.63-0.4396-0.43960.18470.7282------112,645.20--------75.83---258.23--4.08--0.0597--50.83--13.13------
Jacobio Pharmaceuticals Group Co Ltd68.49m-387.24m1.50bn301.00--1.29--21.85-0.5009-0.50090.08861.460.0419--5.21227,556.30-23.66-45.76-26.86-49.305.04---565.36-372.22----0.1636---33.66--3.43--19.18--
TOT Biopharm International Co Ltd841.76m-40.71m1.50bn551.00--2.02285.371.78-0.0562-0.05621.160.95820.58081.878.031,527,700.00-2.81-20.01-3.72-25.2173.5374.74-4.84-68.531.48-4.600.3348--76.5481.8824.36--21.04--
Immunotech Biopharm Ltd0.00-361.04m1.57bn210.00--8.41-----0.7016-0.70160.000.36380.00----0.00-38.88-37.42-50.88-45.48--------1.03-1.970.4327-------5.25------
VIVA Biotech Holdings2.32bn-125.21m1.58bn2.08k--0.393213.130.6788-0.0637-0.06371.201.860.28054.845.211,119,109.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.151.000.3412---9.4259.3178.03--31.98--
Hua Medicine82.61m-227.78m1.67bn177.00--14.20--20.19-0.233-0.2330.08460.11120.05381.6913.03466,720.80-14.84-25.61-17.56-28.8148.78---275.73-1,654.706.06--0.6238--335.31---3.80--14.07--
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn351.53m1.82bn1.14k5.170.58974.021.460.23390.23390.82612.050.31562.316.371,085,997.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
CStone Pharmaceuticals500.17m-395.99m1.82bn230.00--3.70--3.65-0.3139-0.31390.3960.38360.28112.443.722,174,639.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32--52.42--
SinoMab Bioscience Ltd1.47m-262.15m2.02bn215.00--6.01--1,372.21-0.2575-0.25750.00150.3080.0015----6,846.04-26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---11.480.604------14.45--106.81--
Acotec Scientific Holdings Ltd510.96m15.62m2.17bn638.00133.391.5533.164.250.0520.0521.704.460.31360.72133.44800,872.400.9589--1.03--79.65--3.06--9.122.750.1529--19.80---79.35------
Cutia Therapeutics148.40m-2.12bn2.30bn298.00--1.58--15.52-6.97-6.970.48814.78------497,988.90--------51.60---1,426.91--5.38--0.153--1,110.83---253.30------
Abbisko Cayman Ltd20.55m-465.38m2.42bn258.00--1.13--117.87-0.719-0.7190.03183.040.0083--1.4079,661.44-18.74---19.67--100.00---2,264.34------0.0177------12.92------
Data as of May 22 2024. Currency figures normalised to Dawnrays Pharmaceutical (Holdings) Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

10.54%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 202494.63m6.31%
UBS Asset Management (Hong Kong) Ltd.as of 31 Jan 202437.04m2.47%
Dimensional Fund Advisors LPas of 09 May 202411.85m0.79%
Fidelity Investments Canada ULCas of 31 Mar 20247.79m0.52%
CATAM Asset Management AGas of 31 Mar 20213.23m0.22%
Strategic Advisers LLCas of 31 Mar 20242.41m0.16%
Dimensional Fund Advisors Ltd.as of 29 Feb 2024713.22k0.05%
DFA Australia Ltd.as of 31 Mar 2024222.65k0.02%
Acadian Asset Management LLCas of 31 Mar 2024150.04k0.01%
Schroder Investment Management North America, Inc.as of 30 Jun 2019104.00k0.01%
More ▼
Data from 28 Mar 2024 - 16 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.